Comparison · NCT04323592-060d22ab
Exposed to Methylprednisolone vs Non-exposed to Methylprednisolone: Endotracheal Intubation (Invasive Mechanical Ventilation)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Exposed to Methylprednisolone vs Non-exposed to Methylprednisolone: Endotracheal Intubation (Invasive Mechanical Ventilation). Trial comparisons, record NCT04323592-060d22ab. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04323592-060d22ab
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.181 | 0.113 | 0.277 | wilson | |
| Risk in group 2 | 0.289 | 0.205 | 0.39 | wilson | |
| Risk difference, group 1 minus group 2 | -0.108 | -0.23 | 0.0193 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.626 | 0.357 | 1.1 | log | |
| Odds ratio, group 1 over group 2 | 0.543 | 0.264 | 1.12 | log | |
| Number needed to treat, for one fewer participant with the outcome on Exposed to Methylprednisolone than on Non-exposed to Methylprednisolone | 9.25 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Exposed to Methylprednisolone | SARS-CoV-2 positive patients with severe acute respiratory syndrome consecutively treated with methylprednisolone (MP) at prolonged dose.~Inclusion criteria checked, the patient undergo 80mg iv bolus of MP followed by infusion (10cc/h) of MP in 240cc 0.9% saline every day until PaO2/FiO2 increase over 350 and/or CRP decrease below 20mg/L, then MP is administered PO tapering slowly until normal CRP values (+20%) are reached.~Methylprednisolone: after initial 80mg iv bolus followed by 80mg in 240cc 0.9% saline administered iv at 10cc/h speed for at least 7 day or more. Duration of Methylprednisolone treatment depends from CRP and P/F values already described in arm/group description~standard care: usual standard of care:~* respiratory support~* empiric antibiotic therapy~* mechanical ventilation (invasive or noninvasive)~* pronation when possible~* other treatment which can be used are: antivirals, chloroquine, vitamins | 15 | 83 | OG000 |
| Group 2 | Non-exposed to Methylprednisolone | Concurrent patients with the same inclusion/section exclusion criteria never treated with steroids, strictly matched according to gender and age (+/-10 years) and other three parameters:~CRP, SOFA score, PaO2:FiO2 -\> each parameter must be \<20% difference between case and control.~standard care: usual standard of care:~* respiratory support~* empiric antibiotic therapy~* mechanical ventilation (invasive or noninvasive)pronation when possible~* other treatment which can be used are: antivirals, chloroquine, vitamins | 26 | 90 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Endotracheal Intubation (Invasive Mechanical Ventilation)
- Description
- We reported below the number of participants who needed endotracheal intubation during ICU admission
- Time frame
- 28 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome
- NCT number
- NCT04323592
- Phases
- Conditions
- Severe Acute Respiratory Syndrome (SARS) Pneumonia, Coronavirus Infections, ARDS, Human
- Interventions
- Methylprednisolone, standard care
- Lead sponsor
- University of Trieste
- Results first posted
- 2020-06-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04323592?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04323592-060d22ab